vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1164Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПОВТОРНЫХ КУРСОВ ЛЕЧЕНИЯ РИТУКСИМАБОМ ТЯЖЕЛОГО РЕФРАКТЕРНОГО ЮВЕНИЛЬНОГО РЕВМАТОИДНОГО АРТРИТАEFFECTIVENESS AND SAFETY OF REPEATED COURSES OF TREATMENT WITH RITUXIMAB IN PATIENTS WITH SEVERE REFRACTORY IDIOPATHIC ARTHRITISАлексееваЕ.И.AlexeevaE.I.ВалиеваС.И.ValievaS.I.БзароваТ.М.BzarovaT.M.СемикинаЕ.Л.SemikinaE.L.ИсаеваК.Б.IsaevaK.B.ЛисицинА.О.LisitsinA.O.ДенисоваР.В.DenisovaR.V.ГудковаЕ.Ю.GudkovaE.Yu.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20092309201585Вопросы современной педиатрии1930Copyright © Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Гудкова Е., 20092009Алексеева Е., Валиева С., Бзарова Т., Семикина Е., Исаева К., Лисицин А., Денисова Р., Гудкова Е.Alexeeva E., Valieva S., Bzarova T., Semikina E., Isaeva K., Lisitsin A., Denisova R., Gudkova E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1164ReferencesGabriel SE. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Аm. 2001; 27: 269–281.Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Аm. 2001; 27: 269–281.El-Gabalawy HD, Lipsky PE. Why do we not have a cure for rheumatoid arthritis? Arthritis Rheum. 2002; 4 (Suppl. 3): 297–301.El-Gabalawy HD, Lipsky PE. Why do we not have a cure for rheumatoid arthritis? Arthritis Rheum. 2002; 4 (Suppl. 3): 297–301.Насонов Е.Л. Фармакотерапия ревматоидного артрита – взгляд в 21 век. Клиническая медицина. 2005; 6: 8–12.Насонов Е.Л. Фармакотерапия ревматоидного артрита – взгляд в 21 век. Клиническая медицина. 2005; 6: 8–12.Насонов Е.Л. Лечение ревматоидного артрита: современное состояние проблемы. РМЖ. 2006; 14 (8): 573–577.Насонов Е.Л. Лечение ревматоидного артрита: современное состояние проблемы. РМЖ. 2006; 14 (8): 573–577.Textbook of pediatric rheumatology. 5th Ed. Cassidy J., Petty R. Elsevier Saunders. 2005.Textbook of pediatric rheumatology. 5th Ed. Cassidy J., Petty R. Elsevier Saunders. 2005.Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под общей ред. А.А. Баранова. М. 2007. С. 325-339.Алексеева Е.И., Литвицкий П.Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под общей ред. А.А. Баранова. М. 2007. С. 325-339.Woo P., Southwood T.R., Prieur A.M. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.Woo P., Southwood T.R., Prieur A.M. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.Насонов Е.Л. Ритуксимаб в лечении ревматических болезней. Научно–практическая ревматология. 2008; 1 (приложение): 3–10.Насонов Е.Л. Ритуксимаб в лечении ревматических болезней. Научно–практическая ревматология. 2008; 1 (приложение): 3–10.Kotzin B.L. The role of B–cells in the pathogenesis of rheumatoid arthritis. J. Rheumatol. 2005; 73: 14-18.Kotzin B.L. The role of B–cells in the pathogenesis of rheumatoid arthritis. J. Rheumatol. 2005; 73: 14-18.Zhang Z., Bridges S.L. Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North Am. 2001; 27: 335–353.Zhang Z., Bridges S.L. Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum. Dis. Clin. North Am. 2001; 27: 335–353.Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann. Rheum. Dis. 2007; 66: 2-22.Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann. Rheum. Dis. 2007; 66: 2-22.Насонов ЕЛ. Перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология и терапия. 2006; 1 (5): 55–58.Насонов ЕЛ. Перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология и терапия. 2006; 1 (5): 55–58.Насонов Е.Л. Новые направления терапии ревматоидного артрита: перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб). РМЖ. 2006; 25: 1778–1782.Насонов Е.Л. Новые направления терапии ревматоидного артрита: перспективы применения моноклональных антител к В–лимфоцитам (ритуксимаб). РМЖ. 2006; 25: 1778–1782.Smolen J.S., Betteridge N., Breedveld F.C. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 143–150.Smolen J.S., Betteridge N., Breedveld F.C. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 143–150.Finckh A., Ciurea A., Brulhart L. et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007; 56: 1417–1423.Finckh A., Ciurea A., Brulhart L. et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007; 56: 1417–1423.Соловьев С.К., Котовская М.А., Насонов Е.Л. Ритуксимаб в лечении системной красной волчанки. РМЖ. 2005; 13: 1731–1735.Соловьев С.К., Котовская М.А., Насонов Е.Л. Ритуксимаб в лечении системной красной волчанки. РМЖ. 2005; 13: 1731–1735.Насонов Е.Л. Перспективы применения ритуксимаба при аутоиммунных заболеваниях человека. РМЖ. 2007; 15 (26): 1958–1963.Насонов Е.Л. Перспективы применения ритуксимаба при аутоиммунных заболеваниях человека. РМЖ. 2007; 15 (26): 1958–1963.Johnson P., Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin. Oncol. 2003; 30 (Suppl. 2): 3–8.Johnson P., Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin. Oncol. 2003; 30 (Suppl. 2): 3–8.Hansen A., Lipsky P. E., Dorner T. B cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nature Clin. Pracr. Rheumatol. 2007; 3: 561.Hansen A., Lipsky P. E., Dorner T. B cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nature Clin. Pracr. Rheumatol. 2007; 3: 561.Youinou P., Jamin C., Saraux A. B-cell: a logical target for treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2007; 25: 318–328.Youinou P., Jamin C., Saraux A. B-cell: a logical target for treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2007; 25: 318–328.Browning J. L. B–cell move to center stage: novel opportunities for autoimmune disease treatment. Nature Rev. 2006; 5: 564–576.Browning J. L. B–cell move to center stage: novel opportunities for autoimmune disease treatment. Nature Rev. 2006; 5: 564–576.Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at stage to predict autoimmune rheumatic diseases? Arthritis Rheum. 2007; 56: 1736–1744.Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at stage to predict autoimmune rheumatic diseases? Arthritis Rheum. 2007; 56: 1736–1744.Edwards J.C.W., Cambridge G., Leandro M.J. B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. 2006; 20: 915–928.Edwards J.C.W., Cambridge G., Leandro M.J. B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. 2006; 20: 915–928.Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998; 91 (5): 1644–1652.Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998; 91 (5): 1644–1652.McLaughlin P., Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833.McLaughlin P., Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J. Clin. Oncol. 1998; 16: 2825–2833.Panayi G.S. B cell-directed therapy in rheumatoid arthritis clinical experience. J. Rheumatol. Suppl. 2005; 73: 19–24.Panayi G.S. B cell-directed therapy in rheumatoid arthritis clinical experience. J. Rheumatol. Suppl. 2005; 73: 19–24.Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63: 803–843.Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2003; 63: 803–843.Hainsworth J.D. Safety of rituximab in the treatment of B–cell malignancies: implications for rheumatoid arthritis. Arthritis Res. Ther. 2003; 5 (Suppl. 4): 12–16.Hainsworth J.D. Safety of rituximab in the treatment of B–cell malignancies: implications for rheumatoid arthritis. Arthritis Res. Ther. 2003; 5 (Suppl. 4): 12–16.Anolik J.H., Campbell D., Felgar R.E. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.Anolik J.H., Campbell D., Felgar R.E. et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 455–459.Bhat N.M., Lee L.M., van Vollenhoven R.F. et al. VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype. J. Rheumatol. 2002; 29: 2114–2121.Bhat N.M., Lee L.M., van Vollenhoven R.F. et al. VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype. J. Rheumatol. 2002; 29: 2114–2121.Pugh-Bernard A.E., Silverman G.J., Cappione A.J. et al. Regulation of inherently autoreactive VH4–34 B cells in the maintenance of human B–cell tolerance. J. Clin. Invest. 2001; 108: 1061–1070.Pugh-Bernard A.E., Silverman G.J., Cappione A.J. et al. Regulation of inherently autoreactive VH4–34 B cells in the maintenance of human B–cell tolerance. J. Clin. Invest. 2001; 108: 1061–1070.Leandro M.J., Ehrenstein M.R., Edwards J.C. et al. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum. 2003; 48: 378.Leandro M.J., Ehrenstein M.R., Edwards J.C. et al. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum. 2003; 48: 378.Patel K., Berman J., Ferber A. et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am. J. Hematol. 2001; 67: 59–60.Patel K., Berman J., Ferber A. et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am. J. Hematol. 2001; 67: 59–60.Stasi R., Pagano A., Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001; 98: 952–957.Stasi R., Pagano A., Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001; 98: 952–957.Berentsen S., Tjonnfjord G.E., Brudevold R. et al. Favorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br. J. Haematol. 2001; 115: 79–83.Berentsen S., Tjonnfjord G.E., Brudevold R. et al. Favorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br. J. Haematol. 2001; 115: 79–83.Quartier P., Brethon B., Philippet P. et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358: 1511–1513.Quartier P., Brethon B., Philippet P. et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358: 1511–1513.Zecca M., Nobili B., Ramenghi U. et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.Zecca M., Nobili B., Ramenghi U. et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003; 101: 3857–3861.Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003; 14: 1851–1857.Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003; 14: 1851–1857.Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52 (2): 601–607.Levine T.D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52 (2): 601–607.Xiao X., Heeringa P., Hu P. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002; 110: 955–963.Xiao X., Heeringa P., Hu P. et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002; 110: 955–963.Eriksson P. Short term outcome and safety in 5 patients with ANCA-positive vasculitis treated with rituximab. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.Eriksson P. Short term outcome and safety in 5 patients with ANCA-positive vasculitis treated with rituximab. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.Jayne D., Burns S., Smith K. A prospective, open label trial of B-cell depletion with rituximab in refractory systemic vasculitis. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.Jayne D., Burns S., Smith K. A prospective, open label trial of B-cell depletion with rituximab in refractory systemic vasculitis. 11th International Vasculitis and ANCA Workshop 2003. Kidney Blood Pressure Res. 2003; 26: 294.Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001; 40: 205–211.Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001; 40: 205–211.Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Current Opinion Rheumatol. 2004; 16: 180–185.Looney R.J., Anolik J., Sanz I. B cells as therapeutic targets for rheumatic diseases. Current Opinion Rheumatol. 2004; 16: 180–185.Stahl H.D., Szczepanski L., Szechinski J. et al. Rituximab in RA: efficacy and safety from a randomized controlled trial. Ann. Rheum. Dis. 2003; 62: 65.Stahl H.D., Szczepanski L., Szechinski J. et al. Rituximab in RA: efficacy and safety from a randomized controlled trial. Ann. Rheum. Dis. 2003; 62: 65.Emery P., Szczepanski L., Szechinski J. et al. Sustained efficacy at 48 weeks after a single treatment course of rituximab in patients with RA. Arthritis Rheum. 2003; 48: 439.Emery P., Szczepanski L., Szechinski J. et al. Sustained efficacy at 48 weeks after a single treatment course of rituximab in patients with RA. Arthritis Rheum. 2003; 48: 439.Алексеева Е.И, Бзарова Т.М., Семикина Е.Л, Акулова С.С. Опыт применения ритуксимаба у больной с системным ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (6): 96–100.Алексеева Е.И, Бзарова Т.М., Семикина Е.Л, Акулова С.С. Опыт применения ритуксимаба у больной с системным ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (6): 96–100.Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Ритуксимаб: новые возможности лечения тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–30.Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Ритуксимаб: новые возможности лечения тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–30.Wallace C.A., Ruperto N., Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.Wallace C.A., Ruperto N., Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004; 31 (11): 2290–2294.
The authors declare that there are no conflicts of interest present.